[EN] APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS AND METHODS OF USE THEREOF<br/>[FR] INHIBITEURS DE KINASES DE RÉGULATION DU SIGNAL D'APOPTOSE 1 ET LEURS PROCÉDÉS D'UTILISATION
申请人:ENANTA PHARM INC
公开号:WO2018209354A1
公开(公告)日:2018-11-15
The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, ester, stereoisomer, tautomer, solvate, hydrate, or combination thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcohol steatohepatitis disease (NASH).
本发明公开了化合物的结构式(I),或者药学上可接受的盐、酯、立体异构体、互变异构体、溶剂合物、水合物或其组合:这些化合物抑制凋亡信号调节激酶1(ASK-1),与自身免疫性疾病、神经退行性疾病、炎症性疾病、慢性肾脏疾病、心血管疾病相关。本发明还涉及包含上述化合物的药物组合物,用于治疗患有ASK-1相关疾病的受试者。本发明还涉及通过给受试者施用包含本发明化合物的药物组合物来治疗受试者的ASK-1相关疾病的方法。本发明具体涉及治疗与肝脂肪变性相关的ASK-1的方法,包括非酒精性脂肪肝(NAFLD)和非酒精性脂肪肝炎(NASH)。